Initial results of ixekizumab efficacy and safety in real‐world plaque psoriasis patients: a multicentre retrospective study-Reference-Cited by-同舟云学术

Initial results of ixekizumab efficacy and safety in real‐world plaque psoriasis patients: a multicentre retrospective study

Published:2018-11-13 Issue:3 Volume:33 Page:553-559
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:J Eur Acad Dermatol Venereol

Author:

Deza G.¹,Notario J.²,Lopez‐Ferrer A.³,Vilarrasa E.³,Ferran M.¹,del Alcazar E.⁴,Carrascosa J.M.⁴,Corral M.⁵,Salleras M.⁵,Ribera M.⁶,Puig L.³,Pujol R. M.¹,Vidal D.⁷,Gallardo F.¹

Affiliation:

1. Department of Dermatology Hospital del Mar‐Institut Mar d'Investigacions Mèdiques Barcelona Spain

2. Department of Dermatology Hospital Universitari de Bellvitge Hospitalet de Llobregat Spain

3. Department of Dermatology Hospital de la Santa Creu i Sant Pau Barcelona Spain

4. Department of Dermatology Hospital Germans Trias i Pujol Badalona Spain

5. Department of Dermatology Hospital Universitari Sagrat Cor Barcelona Spain

6. Department of Dermatology Hospital Parc Taulí Sabadell Spain

7. Department of Dermatology Hospital Moisès Broggi Sant Joan Despí Spain

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdv.15288

Reference23 articles.

1. Quality of Life in Patients with Psoriasis: A Systematic Literature Review

2. Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence

3. European S3-Guidelines on the systemic treatment of psoriasis vulgaris - Update 2015 - Short version - EDF in cooperation with EADV and IPC

4. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis

5. Ixekizumab: A Review in Moderate to Severe Plaque Psoriasis

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Injection site reactions resulting from the use of biological therapy in the treatment of moderate-to-severe plaque psoriasis;Expert Opinion on Drug Safety;2024-08-17

2. Clinical Characteristics Associated With Response to Biologics in the Treatment of Psoriasis;JAMA Dermatology;2024-08-01

3. Six-Month Real-World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry;Drugs - Real World Outcomes;2024-06-24

4. Choosing the right biologic treatment for moderate-to-severe plaque psoriasis: the impact of comorbidities;Expert Review of Clinical Pharmacology;2024-04-02

5. Paradoxical psoriasis induced by IL-17 antagonists;Indian Journal of Dermatology, Venereology and Leprology;2024-04-02